A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis

Physiological Reports

Volumn 4, Issue 21, 2016, Pages

  Ejima, Chieko ^a   Kuroda, Haruna ^a   Ishizaki, Sonoko ^a  

^a EA Pharma Co   (Japan)

Author keywords

Animal model; Branched chain amino acids; Nonalcoholic steatohepatitis; Screening

Indexed keywords

CHOLESTEROL; DIETHYLNITROSAMINE; TRIACYLGLYCEROL;

ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; FIBROSIS; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; LIVER; MALE; MASS SCREENING; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PROCEDURES;

ANIMALS; CHOLESTEROL; DIET, HIGH-FAT; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; FIBROSIS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MASS SCREENING; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES;

EID: 84995776232     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.13016     Document Type: Article

References (38)

1. Ahmed, A., R. J. Wong, and S. A. Harrison. 2015. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin. Gastroenterol. Hepatol. 13:2062-2070.
2. Arguello, G., E. Balboa, M. Arrese, and S. Zanlungo. 1852. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim. Biophys. Acta 1765-1778:2015.
3. Cha, J. H., S. H. Bae, H. L. Kim, N. R. Park, E. S. Choi, E. S. Jung, et al. 2013. Branched-chain amino acids ameliorate fibrosis and suppress tumor growth in a rat model of hepatocellular carcinoma with liver cirrhosis. PLoS ONE 8: e77899.
4. Deng, Q. G., H. She, J. H. Cheng, S. W. French, D. R. Koop, S. Xiong, et al. 2005. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42:905-914.
5. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
6. Georgescu, E. F., R. Ionescu, M. Niculescu, L. Mogoanta, and L. Vancica. 2009. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15:942-954.
7. Hebbard, L., and J. George. 2011. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8:35-44.
8. Ichimura, M., M. Kawase, M. Masuzumi, M. Sakaki, Y. Nagata, K. Tanaka, et al. 2015. High-fat and highcholesterol diet rapidly induces non-alcoholic steatohepatitis with advanced fibrosis in Sprague-Dawley rats. Hepatol. Res. 45:458-469.
9. Imajo, K., M. Yoneda, T. Kessoku, Y. Ogawa, S. Maeda, Y. Sumida, et al. 2013. Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int. J. Mol. Sci. 14:21833-21857.
10. Ishizaki, S., M. Nishiyama, and A. Hagiwara. 2013. Long-term branched chain amino acid supplementation ameliorates diethylnitrosamine-induced liver glutathione S-transferase-p positivity in Zucker fatty rats. J Clin Exp Hepatol 3:192-197.
11. Itoh, M., T. Suganami, N. Nakagawa, M. Tanaka, Y. Yamamoto, Y. Kamei, et al. 2011. Melanocortin 4 receptordeficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am. J. Pathol. 179:2454-2463.
12. Iwasa, J., M. Shimizu, M. Shiraki, Y. Shirakami, H. Sakai, Y. Terakura, et al. 2010. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamineinduced liver tumorigenesis in obese and diabetic C57BL/ KsJ-db/db mice. Cancer Sci. 101:460-467.
13. Kawaguchi, T., K. Shiraishi, T. Ito, K. Suzuki, C. Koreeda, T. Ohtake, et al. 2014. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin. Gastroenterol. Hepatol. 12:1012-1018.
14. Khanna, V., M. Jain, V. Singh, J. S. Kanshana, P. Prakash, M. K. Barthwal, et al. 2013. Cholesterol diet withdrawal leads to an initial plaque instability and subsequent regression of accelerated iliac artery atherosclerosis in rabbits. PLoS ONE 8:e77037.
15. Listenberger, L. L., X. Han, S. E. Lewis, S. Cases, R. V. Jr Farese, D. S. Ory, et al. 2003. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl Acad. Sci. USA 100:3077-3082.
16. Machado, M. V., G. A. Michelotti, G. Xie, T. P. Almeida, J. Boursier, B. Bohnic, et al. 2015. Mouse models of dietinduced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS ONE 10: e0127991.
17. Matsumoto, M., N. Hada, Y. Sakamaki, A. Uno, T. Shiga, C. Tanaka, et al. 2013. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int. J. Exp. Pathol. 94:93-103.
18. Matsuzawa, N., T. Takamura, S. Kurita, H. Misu, T. Ota, H. Ando, et al. 2007. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46:1392-1403.
19. Mells, J. E., P. P. Fu, P. Kumar, T. Smith, S. J. Karpen, and F. A. Anania. 2015. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J. Nutr. Biochem. 26:285-292.
20. Michelotti, G. A., M. V. Machado, and A. M. Diehl. 2013. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10:656-665.
21. Musso, G., R. Gambino, M. Cassader, and G. Pagano. 2010. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52:79-104.
22. Muto, Y., S. Sato, A. Watanabe, H. Moriwaki, K. Suzuki, A. Kato, et al.; Long-Term Survival Study Group. 2005. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol. 3: 705-713.
23. Nakano, A., Y. Hattori, C. Aoki, T. Jojima, and K. Kasai. 2009. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferatoractivated receptor-gamma. Hypertens. Res. 32:765-769.
24. Paschos, P., and K. Tziomalos. 2012. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 4:327-331.
25. Puri, P., R. A. Baillie, M. M. Wiest, F. Mirshahi, J. Choudhury, O. Cheung, et al. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46:1081-1090.
26. Sahai, A., P. Malladi, X. Pan, R. Paul, H. Melin-Aldana, R. M. Green, et al. 2004. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G1035-G1043.
27. Sanches, S. C., L. N. Ramalho, M. J. Augusto, D. M. da Silva, and F. S. Ramalho. 2015. Nonalcoholic steatohepatitis: A search for factual animal models. Biomed Res Int 2015:574832.
28. Spengler, E. K., and R. Loomba. 2015. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin. Proc. 90:1233-1246.
29. Subramanian, S., L. Goodspeed, S. Wang, J. Kim, L. Zeng, G. N. Ioannou, et al. 2011. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptordeficient mice. J. Lipid Res. 52:1626-1635.
30. Takahashi, Y., Y. Soejima, and T. Fukusato. 2012. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 18:2300-2308.
31. Takakura, K., S. Koido, M. Fujii, T. Hashiguchi, Y. Shibazaki, H. Yoneyama, et al. 2014. Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice. Anticancer Res. 34:4849-4855.
32. Tolba, R., T. Kraus, C. Liedtke, M. Schwarz, and R. Weiskirchen. 2015. Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. Lab. Anim. 49:59-69.
33. Tomita, K., T. Teratani, T. Suzuki, M. Shimizu, H. Sato, K. Narimatsu, et al. 2014. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59:154-169.
34. Varela-Rey, M., N. Embade, U. Ariz, S. C. Lu, J. M. Mato, and M. L. Martinez-Chantar. 2009. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int. J. Biochem. Cell Biol. 41:969-976.
35. Vos, B., C. Moreno, N. Nagy, F. Féry, M. Cnop, P. Vereerstraeten, et al. 2011. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol. Belg. 74:389-394.
36. Watanabe, M., S. M. Houten, C. Mataki, M. A. Christoffolete, B. W. Kim, H. Sato, et al. 2006. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489.
37. Yetti, H., H. Naito, X. Jia, M. Shindo, H. Taki, H. Tamada, et al. 2013. High-fat-cholesterol diet mainly induced necrosis in fibrotic steatohepatitis rat by suppressing caspase activity. Life Sci. 93:673-680.
38. Younossi, Z. M., M. Stepanova, F. Negro, S. Hallaji, Y. Younossi, B. Lam, et al. 2012. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 91:319-327.